We are a fast-growing and dynamic organization seeking a Research Associate, Analytical Sciences to join our CMC team. The Research Associate, Analytical Sciences will support drug substance and drug product physicochemical and biophysical testing for Analytical Sciences (AS) and CMC activities. This individual will be part of a growing team responsible for the development, execution, and data analyses of liquid chromatography (LC), capillary electrophoresis (CE), spectroscopic, and compendial methods supporting clinical and commercial products. The Research Associate will develop, execute, and manage methods used for clinical and commercial testing to support CMC, Discovery, Quality Assurance, Regulatory Affairs, and corporate objectives. The scope of this role includes laboratory testing support for all phases of product development, including clinical and commercial programs, with emphasis on biologics identity, purity, physicochemical, and compendial methods used for in-process, Release, Stability, comparability, and extended characterization testing. Responsibilities also include support and management of external CDMO and contract test lab method transfers, testing, troubleshooting, and investigations. This role will also support internal laboratory management activities. Good things are happening at Omeros! Who is Omeros? Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA ® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway’s key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit www.omeros.com .
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Entry Level
Education Level
Associate degree